An SDG Target We Can Reach: Financing Viral Hepatitis Elimination
The World Health Assembly calls for elimination of viral hepatitis as a public health threat by 2030 and yet most countries are not on track. No major philanthropic funders have committed to this global goal despite the 1.5 million deaths which could be averted and a strong cost-benefit argument.
Existing investments from global partners have proven to catalyze development and scale up of national programs. However, innovative financing and blended finance mechanisms have been vastly underutilized especially when compared to their use for other major disease areas (e.g. malaria, TB, NCDs).
- How to attract capital – public and private – towards projects that contribute to viral hepatitis elimination?
- How can innovative financing increase our efforts in this target?
- Tenu Afavia, Deputy Executive Director, UNITAID
- Rania Al- Mashat, Minister of International Cooperation, Arab Republic of Egypt
- Helen Clark, Former Prime Minister of New Zealand, Board Chair, Partnership for Maternal, Newborn and Child Health (PMNCH)
- Sherine Helmy, CEO, Pharco Pharmaceuticals, Egypt
- John Ward, Task Force for Global Health, USA